Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: Possible behavioural, biochemical and cellular alterations

European Journal of Pharmacology

Volumn 615, Issue 1-3, 2009, Pages 91-101

  Kumar, Puneet ^a   Kumar, Anil ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

3 Nitropropionic acid; Huntington's disease; Mitochondrion; Oxidative stress; Rivastigmine

Indexed keywords

3 NITROPROPIONIC ACID; CATALASE; MITOCHONDRIAL COMPLEX II; MITOCHONDRIAL COMPLEX IV; MITOCHONDRIAL ENZYME; NITRITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RIVASTIGMINE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME BLOOD LEVEL; HIPPOCAMPUS; HUNTINGTON DISEASE LIKE SYNDROME; LIPID PEROXIDATION; LOCOMOTION; MALE; MEMORY CONSOLIDATION; MENTAL PERFORMANCE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT DURATION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; BRAIN CHEMISTRY; CHOLINESTERASE INHIBITORS; CORPUS STRIATUM; HUNTINGTON DISEASE; LIPID PEROXIDATION; MALE; MAZE LEARNING; MITOCHONDRIA; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NITRITES; NITRO COMPOUNDS; OXIDATIVE STRESS; PHENYLCARBAMATES; PROPIONIC ACIDS; RATS; RATS, WISTAR; ROTAROD PERFORMANCE TEST;

EID: 67449155877     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.04.058     Document Type: Article

References (63)

1. Alexi T., Hughes P.E., Faull R.L., and Williams C.E. 3-nitropropionic acid's lethal triplet: cooperative pathways of neurodegeneration. Neuroreport 9 (1998) R57-64
2. Andin J., Enz A., Gentsch C., and Marcusson J. Rivastigmine as a modulator of the neuronal glutamate transporter rEAAC1 mRNA expression. Dement. Geriatr. Cogn. Disord. 19 (2005) 18-23
3. Barquero-Jiménez M.S., and Gómez-Tortosa E. Cognitive disorders in patients with Huntington's disease. Rev. Neurol. 32 (2001) 1067-1071
4. Beal M.F. Energetic in the pathogenesis of neurodegenerative disease. Trends Neurosci. 23 (2000) 298-304
5. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., and Hyman B.T. J. Neurosci. 13 (1993) 4181-4192
6. Becker L.I., Miguel R.D., and Ruzi J.J.F. The endocannabinoid system and Huntington's disease. Current Drug Targets-CNS Neurol. Disord. 2 (2003) 335-347
7. Bejar C., Wang R.H., and Weinstock M. Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur. J. Pharmacol. 383 (1999) Z31-40
8. Berman S.B., and Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73 (1999) 1127-1137
9. Brouillet E., and Hantraye P. Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Curr. Opin. Neurol. 8 (1995) 469-473
10. Brouillet E., Condé F., Beal M.F., and Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59 (1999) 427-468
11. Browne S.E., Ferrante R.J., and Beal M.F. Oxidative stress in Huntington's disease. Brain Pathol. 9 (1999) 147-163
12. Casademont J., Miró O., Rodriguez-Santiago B., Viedma P., Blesa R., and Cardellach F. Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease. J. Neurol. Sci. 206 (2003) 23-26
13. Cassarino D.S., and Bennett Jr. J.P. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res. Rev. 29 (1999) 1-25
14. Cummings J., and Winblad B. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert. Rev. Neurother. 7 (2007) 1457-1463
15. de Tommaso M., Specchio N., Sciruicchio V., Difruscolo O., and Specchio L.M. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov. Disord. 19 (2004) 1516-1528
16. de Tommaso M., Difruscolo O., Sciruicchio V., Specchio N., and Livrea P. Two years' follow-up of rivastigmine treatment in Huntington disease. Clin. Neuropharmacol. 30 (2007) 43-46
17. Ellman G.L., Courtney K.D., Andres V., and Featherston R.M.A. New and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7 (1961) 88-95
18. Figiel G., and Sadowsky C.A. Systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. Curr. Med. Res. Opin. 24 (2008) 157-166
19. Frautschy S.A., Hu W., Kim P., Miller S.A., White-Harris M.E., Chua T., and Cole G.M. Phenolic anti-inflammatory antioxidant reversal of Ab-induced cognitive deficits and neuropathology. Neurobiol. Aging 22 (2001) 993-1005
20. Fu Y., He F., Zhang S., Huang J., Zhang J., and Jiao X. 3-Nitropropionic acid produces indirect excitotoxic damage to rat striatum. Neurotoxicol. Teratol. 17 (1995) 333-339
21. Gao X., and Tang X.C. Huperzine A attenuates mitochondrial dysfunction in beta-amyloid-treated PC12 cells by reducing oxygen free radicals accumulation and improving mitochondrial energy metabolism. J. Neurosci. Res. 83 (2006) 1048-1057
22. Gil J.M., and Rego A.C. Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci. 27 (2008) 2803-2820
23. Gornall A.G., Bardawill C.J., and David M.M. Determination of serum proteins by means of the biuret reaction. J. Biol. Chem. 177 (1949) 751-766
24. 15N] nitrate in biological fluids. Ann. Biochem. 126 (1982) 131-138
25. Hansen R.A., Gartlehner G., Webb A.P., Morgan L.C., Moore C.G., and Jonas D.E. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin. Interv. Aging 3 (2008) 211-225
26. Jann M.W. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 20 (2000) 1-12
27. Keene C.D., Rodrigues C.M., Eich T., Linehan-Stieers C., Abt A., Kren B.T., Steer C.J., and Low W.C. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp. Neurol. 171 (2001) 351-360
28. Kim M.H., Kim M.O., Heo J.S., Kim J.S., and Han H.J. Acetylcholine inhibits long-term hypoxia-induced apoptosis by suppressing the oxidative stress-mediated MAPKs activation as well as regulation of Bcl-2, c-IAPs, and caspase-3 in mouse embryonic stem cells. Apoptosis 13 (2008) 295-304
29. King J. Colorimetric estimation of lactate dehydrogenase. J. Med. Lab. Technol. 16 (1959) 256-261
30. King T.E. Preparation of succinate dehydrogenase and reconstitution of succinate oxidase. Methods Enzymol. 10 (1967) 322-331
31. King T.E., and Howard R.L. Preparations and properties of soluble NADH dehydrogenases from cardiac muscle. Methods Enzymol. 10 (1967) 275-294
32. Kono Y. Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay of superoxide dismutase. Arch. Biochem. Biophy. 186 (1978) 189-195
33. Kulkarni S.K. Handbook of Experimental Pharmacology. 3rd Edition (1999), Vallabh Parkashan, New Delhi, India
34. Kumar P., Padi S.S., Naidu P.S., and Kumar A. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav. Pharmacol. 17 (2006) 485-492
35. Kumar P., Padi S.S., Naidu P.S., and Kumar A. Possible neuroprotective mechanisms of curcumin in attenuating 3-nitropropionic acid-induced neurotoxicity. Methods Find. Exp. Clin. Pharmacol. 29 (2007) 1-7
36. Lim D., Fedrizzi L., Tartari M., Zuccato C., Cattaneo E., Brini M., and Carafoli E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J. Biol. Chem. 283 (2008) 5780-5789
37. Liu X., Luo X., and Hu W. Studies on the epidemiology and etiology of moldy sugarcane poisoning in China. Biomed. Environ. Sci. 5 (1992) 161-177
38. Luck H. Catalase. In: Bergmeyer H.U. (Ed). Methods of Enzymatic Analysis (1971), Academic Press, New York 885-893
39. McGeer P.L., McGeer E.G., and Fibiger H.C. Choline acetylase and glutamic acid decarboxylase in Huntington's chorea. Neurology 23 (1973) 912-918
40. Ming L. Moldy sugarcane poisoning-a case report with a brief review. J. Toxicol. Clin. Toxicol. 33 (1995) 363-367
41. Mosmann T. Rapid colorimetric assay for cellular growth survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
42. Nam E., Lee S.M., Koh S.E., Joo W.S., Maeng S., Im H.I., and Kim Y.S. Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum. Brain Res. 1046 (2005) 90-96
43. Nicholls D.G., and Budd S.L. Mitochondria and neuronal survival. Physiol. Rev. 80 (2000) 315-360
44. Oertel W., Poewe W., Wolters E., De Deyn P.P., Emre M., Kirsch C., Hsu C., Tekin S., and Lane R. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. Drug Safety 31 (2008) 79-94
45. Pan Y., Xu X., and Wang X. Rivastigmine blocks voltage-activated K currents in dissociated rat hippocampal neurons. Br. J. Pharmacol. 140 (2003) 907-912
46. Porsteinsson A.P., Grossberg G.T., Mintzer J., and Olin J.T. Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr. Alzheimer Res. 5 (2008) 83-89
47. Reddy D.S., and Kulkarni S.K. Possible role of nitric oxide in the nootropic and antiamnesic effects of neurosteroids on aging and dizociline induced leaning impairment. Brain Res. 799 (1998) 215-219
48. Rot U., Kobal J., Sever A., Pirtosek Z., and Mesec A. Rivastigmine in the treatment of Huntington's disease. Eur. J. Neurol. 9 (2002) 689-690
49. Shah S., and Reichman W.E. Treatment of Alzheimer's disease across the spectrum of severity. Clin. Interv. Aging. 1 (2006) 131-142
50. Shear D.A., Haik K.L., and Dunbar G.L. Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. Neuroreport 11 (2000) 1833-7183
51. Siddiqui M., Asif A., Wagstaff, and Antona J. Rivastigmine: in Parkinson's disease dementia. CNS Drugs 20 (2006) 739-747
52. Silver J.M., Koumaras B., Chen M., Mirski D., Potkin S.G., Reyes P., Warden D., Harvey P.D., Arciniegas D., Katz D.I., and Gunay I. Effects of rivastigmine on cognitive function in patients with traumatic brain injury. Neurology 67 (2006) 748-755
53. Sottocasa G.L., Kuylenstierna B., Ernster L., and Bergstrand A. An electron-transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J. Cell Biol. 32 (1967) 415-438
54. Stefanova N., Puschban Z., Fernagut P.O., Brouillet E., Tison F., Reindl M., Jellinger K.A., Poewe W., and Wenning G.K. Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). Acta Neuropathol. 106 (2003) 157-166
55. Teunissen C.E., Steinbusch H.W., Angevaren M., Appels M., de Bruijn C., Prickaerts J., and de Vente J. Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation. Neuroscience 105 (2001) 153-167
56. Trushina E., and McMurray C.T. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 145 (2007) 1233-1248
57. Túnez I., Muñoz Mdel C., Feijóo M., Muñoz-Castañeda J.R., Bujalance I., Valdelvira M.E., and Montilla López P. Protective melatonin effect on oxidative stress induced by okadaic acid into rat brain. J. Pineal. Res. 34 (2003) 265-268
58. Túnez I., Feijóo M., Collado J.A., Medina F.J., Peña J., Muñoz Mdel C., Jimena I., Franco F., Rueda I., Muntané J., and Montilla P. Effect of testosterone on oxidative stress and cell damage induced by 3-nitropropionic acid in striatum of ovariectomized rats. Life Sci. 80 (2007) 1221-1227
59. Van Houten B., Woshner V., and Santos J.H. Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair (Amst) 5 (2006) 145-152
60. Wills E.D. Mechanism of lipid peroxide formation in animal. Biochem. J. 99 (1966) 667-676
61. Xiao X.Q., Wang R., Han Y.F., and Tang X.C. Protective effects of huperzine A on beta-amyloid (25-35) induced oxidative injury in rat pheochromocytoma cells. Neurosci. Lett. 286 (2000) 155-168
62. Xiao X.Q., Wang R., and Tang X.C. Huperzine A and tacrine attenuate beta-amyloid peptide-induced oxidative injury. J. Neurosci. Res. 61 (2000) 564-579
63. Zeevalk G.D., Derr-Yellin E., and Nicklas W.J. Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade. J. Pharmacol. Exp. Ther. 275 (1995) 1124-1130